Research programme: BET bromodomain inhibitors - Aurigene

Drug Profile

Research programme: BET bromodomain inhibitors - Aurigene

Alternative Names: Pan BET bromodomain inhibitors programme - Aurigene; Selective BET bromodomain inhibitors programme - Aurigene

Latest Information Update: 29 Nov 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Aurigene Discovery Technologies
  • Developer Aurigene Discovery Technologies; Orion
  • Class Small molecules
  • Mechanism of Action Bromodomain and extraterminal domain protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Cancer

Most Recent Events

  • 08 Sep 2016 Preclinical development is ongoing for Cancer (Aurigene Discovery Technologies pipeline, September 2016)
  • 16 Jul 2016 No recent reports of development identified for preclinical development in Cancer in India (PO)
  • 24 Jun 2014 Aurigene Discovery Technologies enters into an option and research and collaboration agreement with Orion for the development of BET bromodomain inhibitors
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top